11 Best Low Cost Stocks to Buy According to Analysts

Page 3 of 10

8. Sanofi (NASDAQ:SNY)

Forward P/E Ratio: 10.22

Number of Hedge Fund Holders: 24

Analyst Upside Potential: 30.65%

Sanofi (NASDAQ:SNY) is one of the Best Low Cost Stocks to Buy According to Analysts. On September 6, Leerink Partners analyst David Risinger maintained a Buy rating on Sanofi (NASDAQ:SNY) without a price target.

The analyst acknowledged the challenges faced by the company with Amlitelimab in its Phase 3 trial, as the results did not meet the high benchmark set by Dupixent. However, Risinger noted that Amlitelimab can still achieve its primary and secondary endpoints, showing promise as a second-line treatment for atopic dermatitis.

The analyst highlighted the drug’s novel mechanism and the convenience of quarterly dosing, which could help it stand out in the competitive market. Moreover, the safety profile of the drug is also encouraging, with a low rate of adverse events. Risinger remains optimistic for the ongoing and upcoming trials and believes that positive data will strengthen the drug’s position over time.

Sanofi (NASDAQ:SNY) is a France-based healthcare company that researches, develops, manufactures, and markets therapeutic solutions.

Page 3 of 10